# Endocannabinoid System Research: CBD and Glucose Tolerance > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabidiol-glucose-tolerance-clinical-trial/ > **Published:** 2026-04-22T23:15:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:00:25-04:00 > **Clinical Summary:** Explore cannabidiol glucose tolerance clinical trial findings on CBD's impact on glucose metabolism and gut microbiome in overweight adults. --- #### Clinical Takeaway Clinical Takeaway In sedentary adults with overweight or obesity, short-term low-dose CBD treatment did not produce measurable improvements in glucose tolerance or alterations to gut microbiome composition. These pilot findings do not support CBD as a standalone intervention for [glucose metabolism](https://cedclinic.com/tetrahydrocannabinol-brain-glucose-consumption-metabolic-modulation/) in this population, despite epidemiological associations between [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and reduced type 2 diabetes risk. ### #5 Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study. **Citation:** Ewell Taylor R et al. *Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study.* Cannabis and [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). 2026. PMID: 41167732. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 12 Design: 5 Journal: 1 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 **Abstract:** INTRODUCTION: Epidemiological data indicate that regular users of cannabis products may be protected from type 2 diabetes, although the mechanism is not understood. Observations from animal studies suggest that the cannabinoid, cannabidiol (CBD) may protect/improve glucose tolerance; an effect that may be partially mediated by favorable modifications to the gut microbiome. The aims of the current pilot project were to gain initial insight into the influence of short-term CBD ingestion on oral glucose tolerance, the gut microbiome, and inflammation in sedentary adults with overweight or obesity and free from diabetes. MATERIALS AND METHODS: Using a randomized, double-blind, repeated measures, parallel design, oral glucose tolerance was determined in 16 adults (6 males, 10 females) prior to and following 4 weeks of daily ingestion of either placebo or CBD (30 mg every 12 h). Fecal samples were collected at baseline and post-intervention. RESULTS: Compared with placebo, CBD did not influence glucose tolerance (Matsuda Index: placebo-pre 7.6 [5.5], placebo-post 10.1 [5.5], vs. CBD-pre 11.7 [7.9], and hCBD-post 10.1 [10.2]; median [interquartile range]; p > 0.05). Characteristics of the gut microbiome or inflammation were not appreciably modified by CBD or placebo. DISCUSSION: Short-term daily ingestion of low-dose CBD did not appear to favorably modify glucose tolerance in sedentary adults with overweight or obesity. It is possible that CBD may not account for the previously reported protection from type 2 diabetes bestowed to regular users of cannabis products.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41167732/)[DOI ↗](https://doi.org/10.1177/25785125251391085) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol Glucose Tolerance Effects in Obesity](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) Review detailed findings on how cannabidiol affects glucose tolerance in individuals with obesity, highlighting clinical implications. [Read More](https://cedclinic.com/cannabidiol-glucose-metabolism-obesity-effects-study/) [`Cannabidiol & Glucose Tolerance: Clinical Trial Findings`](https://cedclinic.com/short-term-low-dose-cannabidiol-glucose-tolerance-study/) Explore clinical trial data assessing cannabidiol's role in glucose tolerance and metabolic health in overweight adults. [Explore Study](https://cedclinic.com/short-term-low-dose-cannabidiol-glucose-tolerance-study/) [Endocannabinoid System Research: Cannabidiol's Impact on Glucose Tolerance & Gut Health in Obese Adults](https://cedclinic.com/cannabidiol-gut-microbiome-obesity-impact-study/) An in-depth look at how cannabidiol influences glucose tolerance and gut microbiome composition in obese adults. [Learn More](https://cedclinic.com/cannabidiol-gut-microbiome-obesity-impact-study/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20Research%3A%20CBD%20and%20Glucose%20Tolerance&url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-glucose-tolerance-clinical-trial%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabidiol-glucose-tolerance-clinical-trial%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20Research%3A%20CBD%20and%20Glucose%20Tolerance%20https%3A%2F%2Fcedclinic.com%2Fcannabidiol-glucose-tolerance-clinical-trial%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).